Incorporating neoadjuvant chemotherapy (NAC) into the management of patients with localized muscle-invasive bladder cancer (MIBC) improves survival. However, due to multiple factors, NAC is still not effectively used in real-life settings. Moreover, there is are established predictor biomarkers to guide clinicians to choose the most beneficial treatment with the least possible toxicities.